查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1597828

梅毒免疫检测诊断市场：按产品、技术和最终用户划分 - 全球预测 2025-2030

Syphilis Immunoassay Diagnostic Market by Product (Analyzer, Kit & Reagent), Technology (CLIA, ELISA), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

梅毒免疫检测诊断市场2023年估值为3.4949亿美元，预计2024年将达到3.7893亿美元，复合年增长率为8.51%，预计到2030年将达到6.193亿美元。

梅毒免疫检测诊断市场是性行为感染感染 (STI) 医疗保健诊断的重要组成部分，用于早期检测、管理和预防。由于危险行为的增加，梅毒的盛行率在全球范围内不断增加，因此需要先进的诊断解决方案。这些免疫检测，包括酵素结合免疫吸附检测法(ELISA) 和化学冷光免疫检测(CLIA)，是临床实验室和就地检验的关键应用，具有高灵敏度和特异性。最终用户范围从医院和诊断中心到公共卫生实验室和私人诊所，展示了其部署范围的广泛性。市场成长主要是由提高诊断准确性和缩短週转时间的技术进步以及公共卫生倡议和意识提升宣传活动的增加所推动的。存在将人工智慧和机器学习整合到诊断平台中以增强预测分析和患者管理的创新机会。然而，市场扩张受到设备高成本、资源匮乏环境中的准入有限以及阻碍快速创新部署的监管障碍等因素的限制。为了克服这些挑战，公司应专注于具有成本效益的製造技术以及与政府卫生机构的合作伙伴关係，以促进更广泛的取得。增加对医疗点创新（特别是行动医疗技术）的研发力度，有可能大幅扩大市场范围并解决服务欠缺地区的价值差距。竞争格局的特点是技术快速变革和消费者对精准健康诊断的期望不断提高，推动了梅毒免疫检测的强大开发平臺。因此，为了永续成长，相关人员应利用精准医学研究并扩大各种临床试验的合作网络，以检验新的诊断方法。透过使这些倡议与市场需求保持一致并有效解决潜在的限制，公司可以在快速发展的梅毒免疫检测诊断市场中强化其价值提案。

主要市场统计
基准年[2023] 3.4949亿美元
预测年份 [2024] 37893万美元
预测年份 [2030] 6.193 亿美元
复合年增长率（%） 8.51%

市场动态：快速发展的梅毒免疫检测诊断市场的关键市场洞察

供需的动态交互作用正在改变梅毒免疫检测诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球因无保护性行为而感染梅毒的盛行率不断上升
    • 旨在改善医疗基础设施的政府改革
    • 母婴传染导致妊娠梅毒的可能性
  • 市场限制因素
    • 根据疾病的阶段，可能没有任何症状，因此很难诊断早期梅毒。
  • 市场机会
    • 怀孕期间流产、死产和其他异常的发生率增加
    • 快速自动化梅毒螺旋体检测和现场检测解决方案的可用性
  • 市场挑战
    • 对梅毒免疫测量缺乏认识
    • 缺乏熟练的专业人员

波特五力：引领梅毒免疫检测诊断市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解梅毒免疫检测分析诊断市场的外部影响

外部宏观环境因素在塑造梅毒免疫检测诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解梅毒免疫检测分析诊断市场的竞争状况

对梅毒免疫检测诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵梅毒免疫检测分析诊断市场供应商绩效评估

FPNV 定位矩阵是评估梅毒免疫检测诊断市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了梅毒免疫检测诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对梅毒免疫检测分析诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 梅毒感染透过无保护性行为在全球传播
      • 旨在改善医疗基础设施的政府改革
      • 母婴妊娠梅毒机率
    • 抑制因素
      • 在某些阶段，这种疾病可能是无症状的，这使得极早期梅毒的诊断变得困难。
    • 机会
      • 怀孕期间流产、死产和其他异常的发生率增加
      • 提供快速、自动化的梅毒螺旋体检测和现场检测解决方案
    • 任务
      • 对梅毒免疫检测疾病认识不足
      • 缺乏熟练的专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章梅毒免疫检测诊断市场：副产品

  • 分析仪
  • 试剂套件和试剂

第七章梅毒免疫检测诊断市场：依技术分类

  • CLIA
  • 酵素连结免疫吸附试验

第八章梅毒免疫检测诊断市场：依最终用户分类

  • 血库
  • 诊断实验室
  • 医院

第九章 北美和南美梅毒免疫检测诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太梅毒免疫检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲梅毒免疫检测诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biolytical Laboratories
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Elitech Group
  • F. Hoffmann-La Roche Ltd
  • Fujirebio, Inc.
  • Gold Standard Diagnostics by Eurofins Technologies
  • Ortho Clinical Diagnostics by Quidel Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
Product Code: MRR-036CEF508599

The Syphilis Immunoassay Diagnostic Market was valued at USD 349.49 million in 2023, expected to reach USD 378.93 million in 2024, and is projected to grow at a CAGR of 8.51%, to USD 619.30 million by 2030.

The syphilis immunoassay diagnostic market stands as a crucial component in sexually transmitted infection (STI) healthcare diagnostics, vital for early detection, management, and prevention. The rising prevalence of syphilis on a global scale, driven by increasing risk behaviors, necessitates advanced diagnostic solutions. These immunoassays, which include enzyme-linked immunosorbent assays (ELISA) and chemiluminescent immunoassays (CLIA), are key applications in clinical laboratories and point-of-care testing, offering high sensitivity and specificity. End-users range from hospitals and diagnostic centers to public health labs and private clinics, underscoring a broad scope of deployment. Market growth is substantially influenced by heightened public health initiatives and awareness campaigns, alongside technological advancements that improve diagnostic accuracy and reduce turnaround times. Innovative opportunities exist in integrating artificial intelligence and machine learning with diagnostic platforms to enhance predictive analytics and patient management. However, market expansion is tempered by factors such as the high cost of equipment, limited access in low-resource settings, and regulatory hurdles that may stifle swift innovation deployment. To navigate these challenges, companies should focus on cost-effective manufacturing techniques and partnerships with governmental health agencies to facilitate broader accessibility. Strengthening R&D efforts toward point-of-care innovations, particularly in mobile health technologies, could significantly broaden the market reach and address value gaps in underserved regions. The competitive landscape is marked by rapid technological shifts and rising consumer expectations for precision health diagnostics, encouraging a robust pipeline of syphilis immunoassay advancements. Thus, for sustained growth, stakeholders should capitalize on research in precision medicine and expand collaborative networks for diverse clinical trials to validate emerging diagnostic methodologies. By aligning these initiatives with market demands and addressing potential constraints effectively, businesses can enhance their value proposition in the rapidly evolving syphilis immunoassay diagnostic market.

KEY MARKET STATISTICS
Base Year [2023] USD 349.49 million
Estimated Year [2024] USD 378.93 million
Forecast Year [2030] USD 619.30 million
CAGR (%) 8.51%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Syphilis Immunoassay Diagnostic Market

The Syphilis Immunoassay Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of the global syphilis infection caused due to unprotected sex
    • Government reforms targeted towards the betterment of healthcare infrastructure
    • Chances of mother-to-child gestational syphilis
  • Market Restraints
    • In some stages, the disease may be asymptomatic, and problems in diagnosing very early syphilis
  • Market Opportunities
    • Rising rate of abortions, stillbirth, and other abnormalities during pregnancy
    • Availability of rapid, automated treponemal tests and on-the-spot testing solutions
  • Market Challenges
    • Lack of awareness of syphilis immunoassay disease
    • The lack of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Syphilis Immunoassay Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Syphilis Immunoassay Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Syphilis Immunoassay Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Syphilis Immunoassay Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Syphilis Immunoassay Diagnostic Market

A detailed market share analysis in the Syphilis Immunoassay Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Syphilis Immunoassay Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Syphilis Immunoassay Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Syphilis Immunoassay Diagnostic Market

A strategic analysis of the Syphilis Immunoassay Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Syphilis Immunoassay Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biolytical Laboratories, bioMerieux SA, Danaher Corporation, DiaSorin S.p.A., Elitech Group, F. Hoffmann-La Roche Ltd, Fujirebio, Inc., Gold Standard Diagnostics by Eurofins Technologies, Ortho Clinical Diagnostics by Quidel Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Syphilis Immunoassay Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Analyzer and Kit & Reagent.
  • Based on Technology, market is studied across CLIA and ELISA.
  • Based on End User, market is studied across Blood Bank, Diagnostic Lab, and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of the global syphilis infection caused due to unprotected sex
      • 5.1.1.2. Government reforms targeted towards the betterment of healthcare infrastructure
      • 5.1.1.3. Chances of mother-to-child gestational syphilis
    • 5.1.2. Restraints
      • 5.1.2.1. In some stages, the disease may be asymptomatic, and problems in diagnosing very early syphilis
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising rate of abortions, stillbirth, and other abnormalities during pregnancy
      • 5.1.3.2. Availability of rapid, automated treponemal tests and on-the-spot testing solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness of syphilis immunoassay disease
      • 5.1.4.2. The lack of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Syphilis Immunoassay Diagnostic Market, by Product

  • 6.1. Introduction
  • 6.2. Analyzer
  • 6.3. Kit & Reagent

7. Syphilis Immunoassay Diagnostic Market, by Technology

  • 7.1. Introduction
  • 7.2. CLIA
  • 7.3. ELISA

8. Syphilis Immunoassay Diagnostic Market, by End User

  • 8.1. Introduction
  • 8.2. Blood Bank
  • 8.3. Diagnostic Lab
  • 8.4. Hospital

9. Americas Syphilis Immunoassay Diagnostic Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Syphilis Immunoassay Diagnostic Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Syphilis Immunoassay Diagnostic Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Becton, Dickinson and Company
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Biolytical Laboratories
  • 5. bioMerieux SA
  • 6. Danaher Corporation
  • 7. DiaSorin S.p.A.
  • 8. Elitech Group
  • 9. F. Hoffmann-La Roche Ltd
  • 10. Fujirebio, Inc.
  • 11. Gold Standard Diagnostics by Eurofins Technologies
  • 12. Ortho Clinical Diagnostics by Quidel Corporation
  • 13. Siemens Healthineers AG
  • 14. Thermo Fisher Scientific Inc.
  • 15. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET RESEARCH PROCESS
  • FIGURE 2. SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY ANALYZER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KIT & REAGENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CLIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY BLOOD BANK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023